IB Neuro™

MRI and CT dynamic susceptibility contrast (DSC) perfusion processing.

Book a meeting
IB-Neuro-header

Overview

Contrast-enhanced MRI (CE-MRI) is considered the gold standard for evaluating brain tumor response to therapy. Yet, CE-MRI is limited in its ability to distinguish brain tumor recurrence from treatment effect. 

These tissue types can appear identical on CE-MRI despite representing distinctly different responses to therapy. IB Neuro aims to overcome these limitations by using a proprietary leakage correction algorithm which distinguishes between tumor and non-tumor tissue. 

Based on calculations of relative cerebral blood volume (rCBV), heightened areas of vascularity show regions of tumor growth (angiogenesis) and necrotic (dead) tissue that result from post-treatment radiation effect. 

imagingBiometrics

Features

  • The IB Neuro module performs post-processing of dynamically acquired MR datasets to evaluate image intensity variations over time.
  • Using proprietary algorithms, it generates Dynamic Susceptibility Contrast (DSC) parametric images.
  • These include Relative Cerebral Blood Volume (rCBV), Relative Cerebral Blood Flow (rCBF), Time To Peak (TTP), and Mean Transit Time (MTT).

Benefits

  • Quantitative MR DSC Perfusion platform eliminates the need for tissue normalization techniques – no need to draw reference ROIs on contralateral white matter.
  • Aims to helps inform treatment decisions and get patients on the correct treatment course sooner.
  • Guiding biopsy – directs neurosurgeons in sampling the most aggressive “hot spot” of the tumor bed (and avoids the common issue of under-sampling).
  • Guiding surgical resection – to ensure active / viable tumor is fully removed.
  • Monitoring treatment – helps non-invasively assess whether a tumor is responding to treatment, or not, based on rCBV.
  • IB Neuro is validated to provide equivalent rCBV when using 50% less dose of gadolinium-based contrast agent (aka “low flip angle”) on 3T scanners¹

Image examples

IB Neuro

To find out more about this solution or any of the other 140+ applications on the Blackford Platform, please book a discovery call with our team.

review image 1

Book a meeting

We’d welcome the opportunity to learn more about your AI needs and to explain how partnering with Blackford can drive efficiency and provide ongoing value.

Book a Meeting

¹Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, et al. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology. 2020 Jun 9;22(9):1262–75.